Targeting phospholipid remodeling pathway improves insulin resistance in diabetic mouse models

• DOI: 10.1096/fj.202301122rr
• Publication Date: 2023-10-12T12:56:53Z
• Authors: Ye Tian; Wei Lu; Ruicheng Shi; Reagan McGuffee; Richard Lee; David A. Ford; Bo Wang
• Keywords: 2. Zero hunger; Insulins; 1-Acylglycerophosphocholine O-Acyltransferase; Diet, High-Fat; 3. Good health; Mice, Inbred C57BL; Mice; Disease Models, Animal; Diabetes Mellitus, Type 2; Liver; Animals; Insulin; Insulin Resistance; Phospholipids

AbstractPrevious studies have revealed that membrane phospholipid composition controlled by lysophosphatidylcholine acyltransferase 3 (LPCAT3) is involved in the development of insulin resistance in type 2 diabetes. In this study, we aimed to investigate the therapeutic potential of targeting Lpcat3 in the treatment of insulin resistance in diabetic mouse models. Lpcat3 expression was suppressed in the whole body by antisense oligonucleotides (ASO) injection or in the liver by adeno‐associated virus (AAV)‐encoded Cre in high‐fat diet (HFD)‐induced and genetic ob/ob type 2 diabetic mouse models. Glucose tolerance test (GTT), insulin tolerance test (ITT), fasting blood glucose, and insulin levels were used to assess insulin sensitivity. Lipid levels in the liver and serum were measured. The expression of genes involved in de novo lipogenesis was analyzed by real‐time RT‐PCR. Metabolic rates were measured by indirect calorimetry using the Comprehensive Lab Animal Monitoring System (CLAMS). Our data demonstrate that acute knockout of hepatic Lpcat3 by AAV‐Cre improves both hyperglycemia and hypertriglyceridemia in HFD‐fed mice. Similarly, whole‐body ablation of Lpcat3 by ASO administration improves obesity and insulin resistance in both HFD‐fed and ob/ob mice. These findings demonstrate that targeting LPCAT3 could be a novel therapy for insulin resistance.